Using flash glucose monitoring in pregnancies in routine care of patients with gestational diabetes mellitus: a pilot study,Acta Diabetologica

当前位置： X-MOL 学术 › Acta Diabetol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Using flash glucose monitoring in pregnancies in routine care of patients with gestational diabetes mellitus: a pilot study
Acta Diabetologica ( IF 3.1 ) Pub Date : 2023-02-25 , DOI: 10.1007/s00592-023-02042-x
Sophie Bastobbe ₁ , Yvonne Heimann ₁ , Ekkehard Schleußner ₁ , Tanja Groten ₁ , Friederike Weschenfelder ₁

Affiliation

Aim

Flash glucose monitoring (FGM) has been approved for the care of pregnant women with preexisting diabetes since 2017. However, its use in gestational diabetes (GDM) has been critically discussed. Inaccuracy and missing recommendations for target values are the main arguments against the use of FGM in GDM. To date, there is a lack of data to justify routine use of FGM in GDM pregnancies. Consequently, this new technology has been withheld from GDM-patients. Aim of our pilot study was to analyze the impact of FGM use on pregnancy outcomes, patient’s satisfaction and to confirm the safe use in GDM pregnancies.

Methods

Cohort study of 37 FGM-managed GDM pregnancies compared with 74 matched women using self-monitoring of blood glucose (SMBG). Group comparison using nonparametric testing concerning patients characteristic and perinatal outcome focusing on adverse outcomes (preeclampsia, preterm delivery, large for gestational age, C-sections, neonatal intensive care unit admission, hyperbilirubinemia and hypoglycemia). Evaluation of patient’s treatment satisfaction using the “Diabetes Treatment Satisfaction Questionnaire change” (DTSQc) and patient interviews.

Results

No significant differences in patient’s characteristics despite gestational age at diagnosis (FGM with 20 vs. SMBG with 25 weeks). No difference in gestational weight gain, HbA1c progression and perinatal outcome. Treatment satisfaction obtained by the DTSQc revealed a high level of satisfaction with FGM use.

Conclusion

FGM use was well accepted and did not affect perinatal outcome. Use of FGM during pregnancy is safe and non-inferior to the management with SBGM. FGM should be considered as an option in the management of GDM patients.

中文翻译：

在妊娠期糖尿病患者的常规护理中使用快速血糖监测：一项初步研究

目的

自 2017 年以来，快速血糖监测 (FGM) 已获准用于治疗既往患有糖尿病的孕妇。然而，其在妊娠糖尿病 (GDM) 中的应用一直受到严格讨论。目标值的不准确性和缺少建议是反对在 GDM 中使用 FGM 的主要论点。迄今为止，缺乏数据证明在 GDM 妊娠中常规使用 FGM 是合理的。因此，这项新技术一直被 GDM 患者所禁止。我们试点研究的目的是分析 FGM 使用对妊娠结局、患者满意度的影响，并确认在 GDM 妊娠中的安全使用。

方法

与 74 名使用自我血糖监测 (SMBG) 的匹配女性相比，37 名 FGM 管理的 GDM 妊娠的队列研究。使用关于患者特征和围产期结果的非参数检验的组比较，重点关注不良结果（先兆子痫、早产、大于胎龄、剖腹产、新生儿重症监护病房入院、高胆红素血症和低血糖）。使用“糖尿病治疗满意度问卷调查”（DTSQc）和患者访谈评估患者的治疗满意度。